Trials / Terminated
TerminatedNCT00381095
A Study To Evaluate Pregabalin In The Treatment Of Moderate To Severe Chronic Bone Pain Related To Metastatic Cancer
A Randomized Placebo-Controlled Trial Of The Efficacy And Tolerability Of Flexibly Dosed Pregabalin In The Treatment Of Cancer-Induced Bone Pain
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 152 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the analgesic efficacy of flexibly-dosed pregabalin in the adjunctive treatment of subjects with cancer-induced bone pain.
Detailed description
Pfizer decided to discontinue additional enrollment into the study effective Sept 5 2010 after assessing the feasibility of completing this study in a realistic timeframe.The study was not stopped for any safety concerns.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pregabalin | Capsule, Flexible-dosing, Double-blind. Treatment duration is 28 days at 100-600 mg/day administered BID+ taper (6 days). |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2006-12-01
- Primary completion
- 2010-10-01
- Completion
- 2010-10-01
- First posted
- 2006-09-27
- Last updated
- 2021-01-20
- Results posted
- 2011-09-27
Locations
55 sites across 19 countries: United States, Canada, Czechia, Egypt, Finland, France, Hungary, Italy, Mexico, Peru, Philippines, Poland, Russia, South Korea, Spain, Sweden, Taiwan, Thailand, Venezuela
Source: ClinicalTrials.gov record NCT00381095. Inclusion in this directory is not an endorsement.